Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6690 | Ordered by Date (descending)
1 2 3 ... 65 66 67  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Astellas–Adaptimmune: allogenic T-cell therapies, 202001– collab r+d CAR-T + TCR therapies with up to $897.5m for ADAP + up to $552.5m for Astellas 2020-01-14
Illumina–Roche: genomic cancer testing, 202001–201412 collab €na strategic alliance non-excl for NGS-based cancer testing for IVD + CDx 2020-01-13
Incyte–MorphoSys: tafasitamab, 202001– collab + ww excl license incl US co-commercialisation $750m upfront + $1.1b milestones 2020-01-13
MorphoSys–Incyte: investment, 202001 equity investment $150m in new ADSs at premium to share price as part of tafasitamab collab/license agreement 2020-01-13
EQRx–1AB Media: public relations, 202001 service existent by 1AB Media 2020-01-12
EQRx–Alphabet: investment, 202001 financing round Series A totalling $200m incl GV 2020-01-12
EQRx–Andreessen Horowitz: investment, 202001 financing round Series A totalling $200m incl a16z 2020-01-12
EQRx–Arboretum Ventures: investment, 202001 financing round Series A totalling $200m incl Arboretum Ventures 2020-01-12
EQRx–ARCH Venture: investment, 202001 financing round Series A totalling $200m incl ARCH Venture Partners 2020-01-12
EQRx–Casdin Capital: investment, 202001 financing round Series A totalling $200m incl Casdin Capital 2020-01-12
EQRx–Nextech: investment, 202001 financing round Series A totalling $200m incl Nextech 2020-01-12
EQRx–Section 32: investment, 202001 financing round Series A totalling $200m incl Section 32 2020-01-12
EQRx–SEVERAL: investment, 202001 financing round Series A $200m with GV + ARCH Venture Partners + Andreessen Horowitz + Casdin Capital et al. 2020-01-12
Iovance–Cellectis: gene editing technology, 202001– collab + license ww excl for TILs in several cancer indications 2020-01-12
Dermira–Lilly: investment, 202001– acquisition $1.1b cash tender offer at $18.75/share ANNOUNCED 2020-01-10
Tyra Biosciences–Alta Partners: investment, 202001 financing round Series A totalling $50m incl co-lead investor Alta Partners 2020-01-10
Tyra Biosciences–Canaan Partners: investment, 202001 financing round Series A totalling $50m incl co-lead investor Canaan 2020-01-10
Tyra Biosciences–RA Capital Management: investment, 202001 financing round Series A totalling $50m incl co-lead investor RA Capital Management 2020-01-10
Tyra Biosciences–SEVERAL: investment, 202001 financing round Series A $50m co-led by Alta Partners + RA Capital + Boxer Capital et al. 2020-01-10
Tyra Biosciences–Tavistock: investment, 202001 financing round Series A totalling $50m incl co-lead investor Boxer Capital 2020-01-10
Almirall–23andMe: therapeutic antibodies, 202001– license ww to bispecific MAb blocking all 3 isoforms of IL-36 2020-01-09
Element Biosciences–Fidelity: investment, 202001 financing round Series B totalling $80.3m incl new investor Fidelity Management and Research 2020-01-09
Element Biosciences–Foresite Capital: investment, 202001 financing round Series B totalling $80.3m incl existing investor Foresite Capital LLC 2020-01-09
Element Biosciences–JS Capital: investment, 202001 financing round Series B totalling $80.3m incl new investor JS Capital LLC 2020-01-09
Element Biosciences–Rockefeller: investment, 202001 financing round Series B totalling $80.3m incl existing investor Venrock 2020-01-09
Element Biosciences–SEVERAL: investment, 202001 financing round Series B $80.3m with Fidelity + JS Capital + Foresite Capital + Venrock 2020-01-09
Nurix Therapeutics–LifeSci: public relations, 202001 service existent by LifeSci Public Relations 2020-01-09
Sanofi–Nurix Therapeutics: protein degradation drugs, 202001– collab strategic ww $55m upfront + $2.5m milestones using DELigase platform 2020-01-09
NorthSea Therapeutics–BioGeneration Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor BGV 2020-01-08
NorthSea Therapeutics–Forbion: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Forbion 2020-01-08
NorthSea Therapeutics–New Science Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor NSV 2020-01-08
NorthSea Therapeutics–Novo Group: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Novo Seeds 2020-01-08
NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio 2020-01-08
NorthSea Therapeutics–Sofinnova: investment, 202001 financing round Series B totalling €36m incl new + co-investor Sofinnova Investments 2020-01-08
NorthSea Therapeutics–VenBio: investment, 202001 financing round Series B totalling €36m incl new + lead investor VenBio Partners 2020-01-08
Novome Biosciences–Alexandria Real Estate: investment, 202001 financing round Series A totalling $33m incl co-investor Alexandria Venture Investments 2020-01-07
Novome Biotechnologies–5AM Ventures: investment, 202001 financing round Series A totalling $33m incl existing seed + co-investor 5AM Ventures 2020-01-07
Novome Biotechnologies–Alta Partners: investment, 202001 financing round Series A totalling $33m incl co-investor Alta Partners 2020-01-07
Novome Biotechnologies–DCVC: investment, 202001 financing round Series A totalling $33m incl lead investor DCVC Bio 2020-01-07
Novome Biotechnologies–Mayo Clinic: investment, 202001 financing round Series A totalling $33m incl co-investor Mayo Clinic 2020-01-07
Novome Biotechnologies–SEVERAL: investment, 202001 financing round Series A $33m led by DCVC Bio 2020-01-07
PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED 2020-01-07
VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors 2020-01-07
VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed 2020-01-07
VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. 2020-01-07
VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors 2020-01-07
VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures 2020-01-07
VectivBio–WPP: public relations, 202001 service existent by Glover Park Group 2020-01-07
Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund 2020-01-06
Elpiscience–SEVERAL: investment, 201912 financing round Series B $100m led by Hyfinity Investments 2019-12-28
Xyphos Biosciences–Astellas: investment, 201912 acquisition 100% for $120m upfront + $545m milestones 2019-12-27
Xyphos Biosciences–Cooley: financial services, 201912 supply service Cooley legal counsel for acquisition of Xyphos by Astellas 2019-12-27
Xyphos Biosciences–Locust Walk: financial services, 201912 supply service Locust Walk financial advisor for acquisition of Xyphos by Astellas 2019-12-27
Codexis–LHA Investor Relations: public relations, 201912 service existent IR by LHA Investor Relations 2019-12-23
Roche–Codexis: DNA ligase, 201912 royalty bearing ww license to include EvoT4 DNA ligase in NA sequencing products + workflows 2019-12-23
Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc 2019-12-20
Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors 2019-12-20
Savara–SEVERAL: investment, 201912– private placement $26.8m (with potential total proceeds of $75m) to institutional investors leb by Bain Capital LS 2019-12-20
CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance 2019-12-19
Forma Therapeutics–Cormorant Asset Management: investment, 201912 financing round Series D totalling $100m incl co-investor Cormorant Asset Management 2019-12-19
Forma Therapeutics–Janus Henderson: investment, 201912 financing round Series D totalling $100m incl co-investor Janus Henderson Investors funds 2019-12-19
Forma Therapeutics–OTHER: investment, 201912 financing round Series D totalling $100m incl undisclosed healthcare investment fund as co-investor 2019-12-19
Forma Therapeutics–RA Capital Management: investment, 201912 financing round Series D totalling $100m incl lead investor RA Capital Management 2019-12-19
Forma Therapeutics–Samsara BioCapital: investment, 201912 financing round Series D totalling $100m incl co-investor Samsara BioCapital 2019-12-19
Forma Therapeutics–SEVERAL: investment, 201912 financing round Series D $100m led by RA Capital Management 2019-12-19
Forma Therapeutics–Stern IR: public relations, 201703 service existent Stern IR is investor contact 2019-12-19
Forma Therapeutics–Wellington Management: investment, 201912 financing round Series D totalling $100m incl co-investor Wellington Management 2019-12-19
Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies 2019-12-19
Kinnate Biopharma–Eshelman Ventures: investment, 201912 financing round Series B totalling $74.5m incl existing investor Eshelman Ventures 2019-12-19
Kinnate Biopharma–Foresite Capital: investment, 201912 financing round Series B totalling $74.5m incl existing investor Foresite Capital 2019-12-19
Kinnate Biopharma–Nextech Invest: investment, 201912 financing round Series B totalling $74.5m incl new investor Nextech Invest Ltd 2019-12-19
Kinnate Biopharma–OrbiMed: investment, 201912 financing round Series B totalling $74.5m incl new investor OrbiMed 2019-12-19
Kinnate Biopharma–SEVERAL: investment, 201912 financing round Series B $74.5m from OrbiMed + Nextech Invest + Vida Ventures + Foresite + Eshelman 2019-12-19
Kinnate Biopharma–Vida Ventures: investment, 201912 financing round Series B totalling $74.5m incl new investor Vida Ventures LLC 2019-12-19
Promega–Merck (DE): CRISPR technology, 201912– license to CRISPR IP io from Merck to Promega to develop CRISPR-edited cell lines 2019-12-19
BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi 2019-12-18
Deerfield–Duke Univ: translational research, 201912–2029 collab establishm Four Points Innovation up to $130m from Deerfield to finance Duke projects 2019-12-18
Epirium Bio–Adams Street Partners: investment, 201912 financing round Series A totalling $85m incl co-investor Adams Street Partners 2019-12-18
Epirium Bio–ARCH Venture: investment, 201912 financing round Series A totalling $85m incl co-lead investor ARCH Venture Partners 2019-12-18
Epirium Bio–Bluebird Ventures: investment, 201912 financing round Series A totalling $85m incl co-investor Bluebird Ventures 2019-12-18
Epirium Bio–Longevity Fund: investment, 201912 financing round Series A totalling $85m incl co-investor The Longevity Fund 2019-12-18
Epirium Bio–Longitude Capital: investment, 201912 financing round Series A totalling $85m incl co-lead investor Longitude Capital 2019-12-18
Epirium Bio–SEVERAL: investment, 201912 financing round Series A $85m co-led by Longitude Capital + ARCH Venture Partners 2019-12-18
Epirium Bio–Temasek: investment, 201912 financing round Series A totalling $85m incl co-investor Vertex Ventures HC 2019-12-18
KCR CRO–Veeva Systems: clinical research software, 201912– supply adoption of Veeva Vault CTMS by KCR 2019-12-18
ArcherDx–ArrowMark Partners: investment, 201912 financing round Series C totalling $55m incl new + co-investor ArrowMark Partners 2019-12-17
ArcherDx–Boulder Ventures: investment, 201912 financing round Series C totalling $55m incl existing + co-investor Boulder Ventures 2019-12-17
ArcherDx–Driehaus Capital: investment, 201912 financing round Series C totalling $55m incl new + co-investor Driehaus Capital Management 2019-12-17
ArcherDx–Longwood Fund: investment, 201912 financing round Series C totalling $55m incl existing + co-investor Longwood Fund 2019-12-17
ArcherDx–PBM Capital: investment, 201912 financing round Series C totalling $55m incl existing + co-investor BPM Capital + affiliates 2019-12-17
ArcherDx–Perceptive Advisors: investment, 201912 financing round Series C totalling $55m incl existing + lead investor Perceptive Advisors 2019-12-17
ArcherDx–Redmile Group: investment, 201912 financing round Series C totalling $55m incl new + co-investor Redmile Group 2019-12-17
ArcherDx–Sands Capital: investment, 201912 financing round Series C totalling $55m incl existing + co-investor Sands Capital 2019-12-17
ArcherDx–SEVERAL: investment, 201912 financing round Series C $55m led by Perceptive Advisors 2019-12-17
ArcherDx–Soleus Capital: investment, 201912 financing round Series C totalling $55m incl new + co-investor Soleus Capital 2019-12-17
Seer–aMoon: investment, 201912 financing round Series D totalling $55m incl lead investor aMoon Fund 2019-12-17
Seer–SEVERAL: investment, 201912 financing round Series D $55m led by aMoon + incl T Rowe Price + all existing plus other new investors 2019-12-17
Seer–T Rowe Price Associates: investment, 201912 financing round Series D totalling $55m incl funds + accounts advised by T Rowe Price 2019-12-17
Flagship Pioneering–WPP: public relations, 201912 service existent by Ogilvy 2019-12-16
Promethera–SEVERAL: investment, 201912 financing round Series D extension €7.5m bringing total round to €47.2m 2019-12-16
1 2 3 ... 65 66 67  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

» top